skip to content
  1. Home
  2. >
  3. Investment Q&A
You can view 3 more answers this month. Sign up for a free trial for unlimited access.

Investment Q&A

Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.

Q: The GUD investing thesis is largely based on management including past success with Paladin. Paladin was certainly a well run company and created lots of value for shareholders so credit to management is not misplaced. But, do you think that the ultimate success with Paladin was more a function of incredibly lucky timing to have been taken out during a really crazy pharma cycle? In other words, how much credit goes to management and how much goes to a once in a generation crazy pharma cycle?
Read Answer Asked by Joel on July 06, 2018
Q: What can you tell me about Revive Therapeutics. I know it's risky and you likely won't recommend it, but any information would be helpful. The stock has jumped on news of receiving orphan drug status for one of their programs. Is this overly significant? I know it creates excitement, but ultimately how does it add to the actual value of the stock?
Read Answer Asked by Grant on June 28, 2018
Q: Hi team, I would like to add some US health care (which I know you don't cover) to my non-registered account for a long term hold and was wondering which one you like better between SYK and ISRG. I am ok with some risk.
Thanks
Read Answer Asked by Nancy on June 22, 2018
Q: Hello, I am looking to add IHI to the healthcare allocation of my portfolio (10%) but would like to sell one existing holding first. Current healthcare related holdings are JNJ, ABBV, GUD and SIS (although I have SIS filed under Industrials). My question: which of JNJ and ABBV would you advise selling? Thank-you.
Read Answer Asked by Stephen on June 20, 2018
Q: Last week, Resverlogix received a positive confirmation from the FDA that it would likely support approval of BETon MACE based on the result of its Phase 3 study. The stock moved up ~28% today. It shows great promise in treating types of cardiovascular disease. From your experience, is it normal for the FDA to offer a positive comment? Would you have an opinion based on the FDA comment to open a position? I am a prudent investor yet have room for higher risk opportunities.
Thank you
Read Answer Asked by Martin on June 19, 2018
Looking for more? Sign up for a FREE 14 day trial! No credit card required

We invite you to sign up for a 14 day free trial of 5i Research!
Experience all the benefits and tools we have to offer; stock research, model portfolios, Q&A with our experts, and so much more. Join a community of like-minded investors today!